Eckert & Ziegler Acquires Bioscan's Radiopharmaceutical Equipment Business

(Washington DC, USA), a preclinical nanotomographic molecular imaging system provider, to acquire its radiopharmaceutical equipment business. The agreement includes both automated radiopharmaceutical synthesis units and analytical instruments used in quality assurance of radioactive pharmaceuticals. This equipment is used in the worldwide production of radiolabeled molecular imaging agents for nuclear medicine.

Eckert & Ziegler Radiopharma board member, Dr. André Hess, explained, "The products we have acquired ideally enhance our developing equipment business, and ensure we can offer our customers system solutions for the production and quality assurance of radiopharmaceuticals. By such an investment we are broadening our commitment to the North American market."

"Bioscan has been a leading player in radioanalytic and radiochemistry instrumentation for more than thirty years. Over the past five years, the company has increasingly focused on its fast-growing molecular imaging business," said Alex Kleinman, vice president of marketing and business development for Bioscan. "Today's transaction will enable Bioscan to increase investment in its rapidly expanding preclinical imaging product line. We are pleased to be able to entrust our radiopharmaceutical equipment business and the thousands of customers that use Bioscan radioanalytic and radiochemistry instruments every day to a market leader like Eckert & Ziegler."

Related Links:
Eckert & Ziegler
Bioscan